<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03730038</url>
  </required_header>
  <id_info>
    <org_study_id>4-2018-0794</org_study_id>
    <nct_id>NCT03730038</nct_id>
  </id_info>
  <brief_title>Effects of Pitavastatin Treatments on the Plasma Lgi3 Level in the Patients With Dyslipidemia</brief_title>
  <official_title>Effects of Pitavastatin Treatments on the Plasma Lgi3 Level in the Patients With Dyslipidemia: A Randomized Crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Leucine-rich glioma inactivated 3(Lgi3) has been postulated to have a pro-inflammatory
      adipokine that inter-plays with other adipokines in adipogenesis and metabolic inflammation
      according to recent investigations. Thus, in this study, we sought to demonstrate that the
      treatment of statin can decrease Lgi3 level along with the decrease of the atherosclerosis to
      further evaluate the role of Lgi3 in atherosclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who assigned to the pitavastatin treatment first group will be given the
      pitavastatin 4 mg qd treatment for 12 weeks after randomization, followed by wash-out period
      of 3 weeks and life-style modification treatment for 12 weeks. Similarly, patients who
      assigned to the life-style modification treatment first group, will be treated with
      life-style modification treatment for 12 weeks after randomization, followed by wash-out
      period of 3 weeks and pitavastatin treatment for 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2019</start_date>
  <completion_date type="Anticipated">October 9, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Patients who assigned to the pitavastatin treatment first group will be given the pitavastatin, followed by wash-out period and life-style modification treatment. Patients who assigned to the life-style modification treatment first group, will be treated with life-style modification treatment first, followed by wash-out period and pitavastatin treatment.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Lgi3 level</measure>
    <time_frame>At 12 weeks after intervention</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Pitavastatin treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of pitavastatin 4 mg qd for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Life-style modification</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment of pitavastatin 4 mg qd for 12 weeks</intervention_name>
    <description>Treatment of pitavastatin 4 mg qd for 12 weeks</description>
    <arm_group_label>Pitavastatin treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Life-style modification</intervention_name>
    <description>Nutritional support with the meal less than 65% of carbohydrate, less than 30% of fat. Exercise 3-4 times, 30 min</description>
    <arm_group_label>Life-style modification</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 20-80 years

          -  Patients with intermediate or low cardiovascular risks needing the statin treatment

          -  Patients with intermediate or low cardiovascular risks treating the statin treatment

        Exclusion Criteria:

          -  Patients without signed informed consent

          -  Patients with myopathy

          -  Pregnant women or women with potential childbearing

          -  Patients with diabetes

          -  Patients with established coronary artery disease

          -  Patients with heart failure

          -  Life expectancy less than 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Yangsoo Jang, MD, Ph.D</last_name>
      <phone>82-2-2228-8460</phone>
      <email>jangys1212@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>November 1, 2018</study_first_submitted>
  <study_first_submitted_qc>November 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2018</study_first_posted>
  <last_update_submitted>February 7, 2019</last_update_submitted>
  <last_update_submitted_qc>February 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyslipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

